Lefamulin in Patients with Community-Acquired Bacterial Pneumonia Caused by Atypical Respiratory Pathogens: Pooled Results from Two Phase 3 Trials.

Saved in:
Bibliographic Details
Title: Lefamulin in Patients with Community-Acquired Bacterial Pneumonia Caused by Atypical Respiratory Pathogens: Pooled Results from Two Phase 3 Trials.
Authors: Paukner S; Nabriva Therapeutics GmbH, Leberstrasse 20, 1110 Vienna, Austria., Mariano D; Nabriva Therapeutics US, Inc., Fort Washington, PA 19034, USA., Das AF; Das Consulting, Guerneville, CA 95446, USA., Moran GJ; Olive View-UCLA Medical Center, Los Angeles, CA 91342, USA., Sandrock C; Department of Internal Medicine, UC Davis School of Medicine, Sacramento, CA 95817, USA., Waites KB; Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294, USA., File TM Jr; Summa Health, Akron, OH 44304, USA.
Source: Antibiotics (Basel, Switzerland) [Antibiotics (Basel)] 2021 Dec 04; Vol. 10 (12). Date of Electronic Publication: 2021 Dec 04.
Publication Type: Journal Article
Journal Info: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101637404 Publication Model: Electronic Cited Medium: Print ISSN: 2079-6382 (Print) Linking ISSN: 20796382 NLM ISO Abbreviation: Antibiotics (Basel) Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2079-6382
DOI:10.3390/antibiotics10121489